Hero image


The COVID-19 pandemic is an unrivaled scientific and global health challenge. As a company with a long legacy of research in infectious diseases, we have a responsibility to help.

We remain committed

We’ve been committed to trying to develop an effective response to the COVID-19 pandemic since it was first recognized. We know that success will require global collaboration among countries and companies and more. That’s why we’ve entered a partnership to support the manufacturing and supply of Johnson & Johnson’s COVID-19 vaccine and are advancing our investigational antiviral COVID-19 therapy.

Putting patients first

We believe that no one should go without the medicines or vaccines they need. That's why we are taking a number of new steps to support patients.

We're taking a number of new steps to help support patients in the U.S. who may have lost their jobs and insurance coverage and we will continue to ensure access to Merck medicines at no cost for eligible U.S. patients through our Merck Patient Assistance Program.

To learn more about resources Merck has available for patients who need help during the COVID-19 pandemic and beyond, call 1-800-672-6372 or visit our information page.

Advancing our therapeutic candidate

In partnership with Ridgeback Bio, we're evaluating our investigational oral antiviral therapy for COVID-19. We're hopeful that we can make a meaningful impact on the pandemic and help patients around the world.

Learn more about our COVID-19 research and find a clinical trial

Expanding manufacturing capacity and supply of COVID-19 medicines and vaccines

In March 2021, we announced an agreement with BARDA to adapt and make available a number of the company’s manufacturing facilities for production of COVID-19 vaccines and medicines. Additionally, we announced agreements with Johnson & Johnson to support manufacturing and supply of Johnson & Johnson’s SARS-CoV-2/COVID-19 vaccine.

Stepping up as an industry

The remarkable pace of the development of COVID-19 vaccines and medicines is good news for our industry and for society – and the direct result of sustained investments in research and development by the research-based pharmaceutical industry, smaller biotechnology companies, academia and governments.  We applaud these efforts – which must continue.

Giving back

In response to the pandemic, we changed our volunteer policy to support employees with nursing and other medical backgrounds. 

Recognizing the need for additional health care professionals, including doctors, nurses and medical laboratory technicians, to assist in regions where COVID-19 is spreading, on March 21 we deployed a new program to enable our medically trained employees to volunteer their time to aid their communities while maintaining their base pay.

Learn more about philanthropy at Merck

Stories that inspire our work

Our work in the fight against COVID-19 reaches across all corners of our company, our personal lives and our communities, where many of our medically trained employees have volunteered their time.